Drug Profile
Lenzilumab - Humanigen
Alternative Names: Humaneered® anti-human GM-CSF monoclonal Antibody; KB-003; LENZ®Latest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator KaloBios Pharmaceuticals
- Developer Humanigen; KaloBios Pharmaceuticals; Kite Pharma; National Institute of Allergy and Infectious Diseases; Peter MacCallum Cancer Centre
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Cytokine release syndrome
- Phase III COVID 2019 infections
- Phase II/III Graft-versus-host disease
- Phase II Chronic myelomonocytic leukaemia
- Phase I/II Drug hypersensitivity
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Discontinued Asthma; B-cell lymphoma; Rheumatoid arthritis
Most Recent Events
- 03 Jan 2024 Taran Therapeutics plans to acquire lenzilumab
- 09 Dec 2023 Updated efficacy and adverse events data from the phase II/III PREACH-M trial in Chronic myelomonocytic leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 08 Jun 2023 Efficacy and adverse events data from a phase II/III trial in Chronic myelomonocytic leukaemia presented at the 28th Congress of the European Haematology Association (EHA-2023)